An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International

Approval of the vasopressin V2 receptor antagonist tolvaptan-based on the landmark TEMPO 3:4 trial-marked a transformation in the management of autosomal dominant polycystic kidney disease (ADPKD). This development has advanced patient care in ADPKD from general measures to prevent progression of chronic kidney disease to targeting disease-specific mechanisms. However, considering the long-term nature of this treatment, as well as potential side effects, evidence-based approaches to initiate treatment only in patients with rapidly progressing disease are crucial. In 2016, the position statement issued by the European Renal Association (ERA) was the first society-based recommendation on the use of tolvaptan and has served as a widely used decision-making tool for nephrologists. Since then, considerable practical experience regarding the use of tolvaptan in ADPKD has accumulated. More importantly, additional data from REPRISE, a second randomized clinical trial (RCT) examining the use of tolvaptan in later-stage disease, have added important evidence to the field, as have post hoc studies of these RCTs. To incorporate this new knowledge, we provide an updated algorithm to guide patient selection for treatment with tolvaptan and add practical advice for its use

An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International

Approval of the vasopressin V2 receptor antagonist tolvaptan—based on the landmark TEMPO 3:4 trial—marked a transformation in the management of autosomal dominant polycystic kidney disease (ADPKD). This development has advanced patient care in ADPKD from general measures to prevent progression of chronic kidney disease to targeting disease-specific mechanisms. However, considering the long-term nature of this treatment, as well as potential side effects, evidence-based approaches to initiate treatment only in patients with rapidly progressing disease are crucial. In 2016, the position statement issued by the European Renal Association (ERA) was the first society-based recommendation on the use of tolvaptan and has served as a widely used decision-making tool for nephrologists. Since then, considerable practical experience regarding the use of tolvaptan in ADPKD has accumulated. More importantly, additional data from REPRISE, a second randomized clinical trial (RCT) examining the use of tolvaptan in later-stage disease, have added important evidence to the field, as have post hoc studies of these RCTs. To incorporate this new knowledge, we provide an updated algorithm to guide patient selection for treatment with tolvaptan and add practical advice for its use

Ordonnancement à machines parallèles avec serveur

Nous présentons dans ce document une approche peu courante pour l'ordonnancement dans les réseaux informatiques. Elle est basée sur l'étude comportementale des entités du réseau lors de l'exécution d'une application distribuée. Nous commençons par une introduction aux problèmes d'ordonnancement suivie des notions nécessaires à la compréhension des modèles d'architecture informatique, du parallélisme et des applications distribuées. Des analyses précises de résultats expérimentaux nous fournissent les éléments nécessaires pour se positionner au sein de la typologie couramment employée en ordonnancement d'atelier. Au cours de celles-ci nous avons pu extraire plusieurs problèmes d'ordonnancement d'atelier pouvant correspondre à la problématique. Nous avons commencé par étudier ceux à machines parallèles identiques avec un serveur qui semblaient pertinents. Toutefois, leur approximation trop légère nous a contraint à nous tourner vers le flow shop hybride qui constitue une approche plus intéressante. L'étude de ce dernier nous a permis de trouver plusieurs résultats théoriques ainsi que des algorithmes efficaces pour sa résolution.We present in this PhD thesis an unusual approach for computer system scheduling. It's based on the study of the network entities behaviour during the execution of a distributed application in order to modelize the problem before establishing algorithms for its resolution. We start with an introduction to the scheduling problems and we introduce the notions necessary to the understanding of the computer architecture models, to parallelism and to the distributed applications. Precise analyses of some experimental results give us the necessary elements to place oneself in the typology currently employed in workshop scheduling. During these analyses we could extract several workshop scheduling problems. We started with studying the identical parallel machines problems with a single server, which at first sight seemed judicious. However their too slight approximation forced us to turn towards the hybrid flow shop which constitutes a more interesting approach. The study of that one enabled us to find several theoretical results as well as some algorithms efficient for its resolution.TOURS-BU Sciences Pharmacie (372612104) / SudocTOURS-Polytech'Informat.Product. (372612209) / SudocSudocFranceF

An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International

Approval of the vasopressin V2 receptor antagonist tolvaptan-based on the landmark TEMPO 3:4 trial-marked a transformation in the management of autosomal dominant polycystic kidney disease (ADPKD). This development has advanced patient care in ADPKD from general measures to prevent progression of chronic kidney disease to targeting disease-specific mechanisms. However, considering the long-term nature of this treatment, as well as potential side effects, evidence-based approaches to initiate treatment only in patients with rapidly progressing disease are crucial. In 2016, the position statement issued by the European Renal Association (ERA) was the first society-based recommendation on the use of tolvaptan and has served as a widely used decision-making tool for nephrologists. Since then, considerable practical experience regarding the use of tolvaptan in ADPKD has accumulated. More importantly, additional data from REPRISE, a second randomized clinical trial (RCT) examining the use of tolvaptan in later-stage disease, have added important evidence to the field, as have post hoc studies of these RCTs. To incorporate this new knowledge, we provide an updated algorithm to guide patient selection for treatment with tolvaptan and add practical advice for its use